Company: SHPH
Filing Date: 2025-04-22
Form Type: PRER14A
Source: 0001641172-25-005648
Chunk: 1

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-22
Form: PRER14A
Chunk 1
---
 adjusted and determined based on market conditions at the time of the offering; and Proposal No. 8, approval of the issuance of in excess of 20% of the Company’s outstanding common stock at a price less than the “Minimum Price” pursuant to a planned $5.0 million to $10.0 million securities offering in accordance with an equity line of credit agreement. Both of these proposals concern planned offerings that the Company is intending to pursue and such proposals are further described in this Additional Proxy Material.

The Additional Proxy Material contained herein is being distributed to the Company’s stockholders separately from the Proxy Statement that was mailed to stockholders beginning April 21, 2025. As our Annual Meeting is scheduled for May 9, 2025, we encourage you to follow the instructions on your proxy cards and vote by telephone or online to ensure your vote is timely received. Your vote is important to us and we encourage you to cast your vote on all matters described in the Proxy Statement and this Additional Proxy Material. We are thankful to our stockholders and encourage everyone to vote on these additional matters in order to ensure the Company is able to effectively raise capital to support our ongoing Phase 2 clinical trials.

| Sincerely,               |
| /s/ Anatoly              
 Dritschilo               |
| Anatoly Dritschilo, M.D. |
| Chairman of the Board of 
 Directors                |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLdIngS, InC.

Additional proxy Statement

for the 2025 annual meeting of stoCkholders

To be held May 9, 2025</div>

This additional proxy material, dated April 21, 2025 (the “Supplement”), supplements and is in addition to the definitive proxy statement (the “Proxy Statement”) of the Board of Directors of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (“SEC”) on April 21, 2025 related to the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled to be held virtually on May 9, 2025 at 12 p.m. ET at www.virtualshareholdermeeting.com/SHPH2025.

The purpose of this Supplement is to seek stockholder approval for the Company to obtain financing through the sale of common stock, or preferred stock convertible into common stock, in excess of 20% of the Company’s outstanding common stock at a price lower than